- Home
- BGNE
BGNE
BeiGene Ltd.
as 12-18-2024 2:32pm EST
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
| Founded: | 2010 | Country: | Cayman Islands |
| Employees: | N/A | City: | GRAND CAYMAN |
| Market Cap: | 19.2B | IPO Year: | 2016 |
| Target Price: | $253.69 | AVG Volume (30 days): | 467.6K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $126.97 - $248.16 | Next Earning Date: | 11-12-2024 |
| Revenue: | $3,351,304,621 | Revenue Growth: | 50.22% |
| Revenue Growth (this year): | 969.39% | Revenue Growth (next year): | 24.79% |
Latest BeiGene Ltd. News
BGNE Breaking Stock News: Dive into BGNE Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Sector Update: Health Care
MT Newswires
5 days ago
BeiGene Enters Global Licensing Agreement with CSPC Zhongqi for Experimental Cancer Therapy
Business Wire
6 days ago
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
MT Newswires
6 days ago
Beigene Insider Sold Shares Worth $7,805,106, According to a Recent SEC Filing
Business Wire
9 days ago
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
Business Wire
14 days ago
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
GuruFocus.com
15 days ago
BeiGene Gains Overweight Rating from Morgan Stanley with $300 Price Target
Insider Monkey
16 days ago
Why Is BeiGene, Ltd. (BGNE) Among the Best High Growth Healthcare Stocks to Invest In Now?
Compare BGNE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BGNE BeiGene Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.